期刊
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY
卷 22, 期 5, 页码 594-602出版社
OXFORD UNIV PRESS
DOI: 10.1177/2047487314522137
关键词
Vitamin D; 25-hydroxyvitamin D; calcifediol; coronary artery disease; atherosclerosis; disease progression; coronary angiography
资金
- Norwegian Ministry of Health and Care Services
- Western Norway Regional Health Authority
- Department of Heart Disease at Haukeland University Hospital, Bergen
- Meltzer Foundation, Bergen, Norway
Background Low vitamin D status is associated with increased risk of cardiovascular disease and may be involved in atherosclerosis. Our aim was to assess the association between vitamin D status and the progression of coronary artery disease (CAD). Methods and Results We measured 25-hydroxyvitamin D3 (25OHD3) by liquid chromatography tandem mass spectrometry (LC-MS/MS) in plasma from 348 participants with established CAD (84% males, meanstandard deviation (SD) age 6010 years) of the Western Norway B-vitamin Intervention Trial (WENBIT, 1999-2006). The patients underwent invasive coronary angiography (CA) and percutaneous coronary intervention at baseline and a second CA after 302 +/- 79 days of follow-up. From the angiograms, minimal lumen diameter (MLD) and diameter stenosis (DS) of atherosclerotic lesions were obtained. Significant CAD in non-intervened vessels was found in 309 coronary arteries from 183 participants either at baseline and/or at follow-up. To assess the association between levels of 25OHD3 and CAD progression in non-intervened vessels, we applied a linear quantile fitted mixed effects model with MLD or DS measured at follow-up as a function of continuous 25OHD3 concentrations. There were no statistically significant associations between plasma 25OHD3 concentrations (median: 63.9, 95% confidence interval (CI): 48.1-78.5nmol/l) measured at baseline and the follow-up measures of either MLD (estimated effect per 10nmol/l increase of 25OHD3 and 95% CI: -0.015 (-0.032-0.002) mm, p=0.088) or DS (0.225 (-0.354-0.804) percentage points, p=0.444). Multivariate adjustment did not alter these results. Conclusion Plasma 25OHD3 levels were not associated with one-year' progression of CAD, assessed by CA in statin-treated patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据